Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2350
https://www.valueinhealthjournal.com/article/S1098-3015(14)04280-6/fulltext
Title :
Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04280-6&doi=10.1016/j.jval.2014.08.2350
First page :
A648
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1806